Immix Biopharma, Inc. (IMMX) News
Follow Immix Biopharma, Inc. (IMMX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 16 public stories across 6 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
BofA Raises Odds Of Success For Immix Biopharma’s NXC-201 Therapy — Sees Over 190% Upside In IMMX Stock
Immix Biopharma (IMMX) was in focus on Tuesday as BofA grew more confident in the prospects for its lead CAR-T therapy, NXC-201, following encouraging new clinical data in a rare disease characterized by harmful protein
EQUITY | Sep 29, 2026, 05:49 PM UTC
L
Immix Biopharma Is Maintained at Buy by Needham
Ratings actions from Benzinga: GMT) Immix Biopharma Price Target Raised to $30.00/Share From $21.00 by NeedhamRatings actions from Benzinga
NEWS | Sep 29, 2026, 05:05 PM UTC
L
Needham maintains Buy rating on Immix Biopharma, $30 price target
Needham maintained their Buy rating on Immix Biopharma's stock with a price target of $30.00.The price target implies an upside of 161.6% from the Sep 28 close of $11.47.Key takeaways from the analyst noteStrong Clinical
EQUITY | Sep 29, 2026, 04:54 PM UTC
L
Immix Biopharma, Inc. (IMMX) Reports 89% CR in NEXICART-2; MRD May Lift to 98%
Immix Biopharma reported an 89% complete response rate (40/45) in an interim NEXICART-2 update. Four MRD-negative pending patients may lift CR up to 98% (44/45). No relapses or neurotoxicity observed to-date; final reado
CENTRAL_BANK | Sep 29, 2026, 11:09 AM UTC
L
Immix Biopharma, Inc. (IMMX) Prices $125M Stock Offering at $11
Immix Biopharma priced an underwritten offering of 11,363,637 common shares at $11.00 per share for gross proceeds of $125M, expected to close on or about Sept. 30, 2026, subject to customary conditions.Material DetailsC
EQUITY | Sep 29, 2026, 11:09 AM UTC
L
Immix Biopharma Announces 89% Complete Response Rate At Interim Update Across All Nexicart-2 Patients, With Mrd-Negativity Indicating Potential To Reach Up To 98% Complete Response Rate
Immix Biopharma, Inc. NASDAQ:IMMX
CENTRAL_BANK | Sep 29, 2026, 11:08 AM UTC
L
Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock
LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten
EQUITY | Sep 29, 2026, 11:08 AM UTC
L
Immix Biopharma interim NEXICART-2: 89% CR rate; MRD suggests up to 98% CR, BLA planned mid-2027
Immix Biopharma reported an 89% complete response rate (40/45) in the Phase 2 NEXICART-2 trial, with MRD-negativity in pending patients indicating a potential to reach up to 98% CR.Key Highlights:Original SEC Filing: Imm
CENTRAL_BANK | Sep 29, 2026, 11:03 AM UTC
L
Immix Biopharma Is Maintained at Outperform by Mizuho
Ratings actions from Benzinga
NEWS | Sep 15, 2026, 01:52 PM UTC
L
IMMX: NXC-201 shows strong efficacy and safety in AL amyloidosis, with pivotal data and BLA submission ahead
NXC-201, a novel CAR T therapy for AL amyloidosis, demonstrates rapid, deep responses and a favorable safety profile, with regulatory designations supporting accelerated review. A pivotal readout and BLA submission are e
NEWS | Sep 14, 2026, 11:01 PM UTC
L
IMMX: NXC-201 demonstrates rapid, durable responses and strong safety in AL amyloidosis, advancing toward approval
NXC-201, a novel CAR T therapy for AL amyloidosis, shows high complete response rates, rapid and durable efficacy, and a favorable safety profile. Regulatory designations and a strong cash position support accelerated ap
NEWS | Sep 14, 2026, 10:07 PM UTC
L
IMMX Initiated Buy W/$21.00 PT at Needham
IMMX Initiated Buy W/$21.00 PT at Needham
EQUITY | Jul 22, 2026, 12:02 PM UTC
L
IMMX -14% - earlier pre-mkt 1-sentence 8-K filing from the company: "As of July 17, 2026, Richard Graydon has been terminated and is no long
IMMX -14% - earlier pre-mkt 1-sentence 8-K filing from the company: "As of July 17, 2026, Richard Graydon has been terminated and is no longer with the Company for reasons unrelated to his activities at the Company. Give
EQUITY | Jul 20, 2026, 02:41 PM UTC
L
IMMX -8% on day after CMO dismissed
IMMX -8% on day after CMO dismissed
EQUITY | Jul 20, 2026, 01:48 PM UTC
L
IMMX A most-wanted fugitive appears to have been secretly working as a Biotech executive Link To Story from STATNEWS.com
IMMX A most-wanted fugitive appears to have been secretly working as a Biotech executive Link To Story from STATNEWS.com
EQUITY | Jul 20, 2026, 01:46 PM UTC
M
IMMX: BofA Initiates Buy
B of A Securities initiates coverage on Immix Biopharma with a buy rating and a price target of $27
EQUITY | Jun 18, 2026, 10:55 AM UTC